ABT Q1 2026 Earnings Analysis
Abbott delivered Q1 adjusted EPS of $1.15 (+6% YoY) with 3.7% comparable sales growth, completed Exact Sciences acquisition on 03/23/2026, and raised FY2026 comparable sales guidance to 6.5%-7.5% with EPS midpoint of $5.48.
Key Metrics
Key Takeaways
- Exact Sciences acquisition closed 03/23/2026, adding ~$3B incremental 2026 sales; comparable growth methodology provides clean apples-to-apples visibility.
- Medical Devices delivered strong results: Electrophysiology +13%, Rhythm Management +13%, Heart Failure +12%; CGM $2B sales grew 7.5% with double-digit growth expected Q2.
- Nutrition pricing actions showing early volume recovery; Core Lab Diagnostics +3% with China stabilizing; Cancer Diagnostics +13% driven by Cologuard mid-teens growth.
Listen On
Available In
Transcript
// Full episode scriptBETA FINCH PODCAST SCRIPT
Welcome to Beta Finch, your AI-powered earnings breakdown! I'm Alex, and I'm here with my co-host Jordan to dive into Abbott Laboratories' Q1 2026 earnings call. Jordan, this was a pretty significant quarter for Abbott - they just closed their acquisition of Exact Sciences back in March.
Absolutely, Alex. And before we jump in, I need to mention that this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.
Thanks for that reminder. So let's talk numbers first. Abbott reported adjusted earnings per share of $1.15 for Q1, which was right in line with their guidance despite some headwinds. Revenue-wise, they're now reporting what they call "comparable growth" of 3.7%, which includes Exact Sciences in both current and prior year numbers.
That comparable growth metric is really interesting, Alex. CEO Robert Ford explained they're doing this to give investors a cleaner apples-to-apples view of the combined business. It's similar to what they did during COVID when they separated out COVID sales, or when they acquired St. Jude. The goal is transparency.
Right, and looking forward, they've updated their full-year guidance to 6.5% to 7.5% comparable sales growth. But here's what caught my attention - their adjusted EPS guidance midpoint dropped from $5.68 to $5.48. That $0.20 dilution is directly from the Exact Sciences acquisition, which was expected.
Let's break down the business segments because there were some really interesting dynamics. Medical Devices was the star performer with 8.5% growth. The Electrophysiology business grew 13%, and get this - they had earlier-than-planned approvals for two new pulsed field ablation catheters.
Those PFA catheters are a big deal, Jordan. The Volt PFA catheter helped drive 14% growth in the U.S., while the TactiFlex Duo catheter contributed to mid-teens growth in Europe. Ford seemed pretty bullish about acceleration in the EP business as these launches broaden.
And speaking of acceleration, the continuous glucose monitoring business had some interesting dynamics. CGM sales were $2 billion but only grew 7.5% due to an international tender delay and some tough comparisons from last year's shelf restocking. But management expects a return to double-digit growth in Q2.
That's a key point. During the Q&A, Ford was asked about concerns that the CGM market might be saturated. His response was fascinating - he said they estimate 70 to 80 million people globally should be on CGM, but the current market is only 10 to 12 million people. That's massive underpenetration.
He also mentioned some upcoming catalysts, including expected CMS coverage for type 2 non-insulin patients, which could add close to 10 million people who currently don't have coverage. Ford was very clear he hadn't baked that into guidance, so it could be upside if it materializes.
Now let's talk about the Exact Sciences integration. This was really the elephant in the room. Ford named Jake Orville to lead that business, reporting directly to him. The Cologuard business grew 13% on a comparable basis, with mid-teens growth of the core Cologuard product.
What struck me was Ford's long-term vision here. He doesn't see this as just a one-product deal, but as a beachhead into the entire cancer diagnostics space - screening, therapy selection, and MRD testing. He pointed out that about 50 million Americans aren't up to date with colorectal cancer screening.
And internationally, Ford said it's very underpenetrated. Abbott brings established regulatory and distribution relationships that could really accelerate international expansion. He even mentioned traveling to Asia and Europe where health ministers listed cancer screening as a top-three priority.
The Nutrition business continues to be a turnaround story. Sales were slightly ahead of expectations, but they're still dealing with the impact of strategic pricing actions implemented in 2025. The good news is Ford said early data indicates they're seeing volume growth beginning to follow their pricing actions.
That's crucial because Nutrition has been a drag on growth. Ford emphasized they did comprehensive price assessments at the product and geographic level, focusing on products that would show positive volume response to price reductions. He specifically called out the Ensure brand in U.S. Adult Nutrition as showing volume growth.
One thing that came up in the Q&A was about respiratory season impact. They had forecasted Q1 to be relatively weak for respiratory virus testing, but it was even weaker than expected. Ford made the prudent decision not to assume they'll make up that shortfall in Q4 with an above-average flu season.
Smart move. He said they have the manufacturing, distribution, and sales force ready if there's a strong respiratory season, but he's not going to bank on it for guidance purposes. Speaking of guidance philosophy, Ford was pretty clear about his approach - they want to provide transparent, detailed breakdowns like they did during COVID.
The Core Lab Diagnostics business showed some encouraging signs too. Sales in China were flat in Q1 after being down 15% to 30% every quarter last year due to volume-based procurement headwinds. Ford said about 80% of their portfolio has now gone through VBP, so they're largely through that cycle.
And in the U.S., Core Lab is performing really well with high single-digit growth rates and 90%+ contract renewal rates. Ford said their win rate on new business is 55%+ - basically winning one out of every two opportunities. That's solid market share gain territory.
Looking at the big picture, what really came through was Ford's confidence about acceleration in the second half. He laid out three key drivers: executing the Nutrition turnaround strategy, accelerating growth in Electrophysiology and Core Lab Diagnostics with new products and improving market conditions, and successfully integrating the high-growth Exact Sciences business.
The diversification story really shines through here, Jordan. Even with some individual segments facing headwinds, the portfolio approach is working. Medical Devices and EPD (their international pharma business) continue delivering consistent growth while they work through the challenges in Nutrition and some geographic headwinds in Diagnostics.
Exactly. And that pipeline Ford mentioned is pretty impressive - they're preparing to initiate several clinical trials in the second half including a balloon-expandable TAVR valve, leadless conduction system pacing, mitral replacement valve, peripheral IVL device, and even a wearable lactate monitoring sensor for sepsis.
Those are all potentially significant market opportunities. The innovation engine at Abbott seems to be firing on all cylinders, which should set them up well for the next few years.
Before we wrap up, I want to remind our listeners that everything we've discussed today is AI-generated analysis for educational purposes. Past performance doesn't guarantee future results. Please do your own due diligence.
Thanks Jordan. Abbott's Q1 shows a company managing through some near-term headwinds while positioning for long-term growth through strategic acquisitions and continued innovation. The Exact Sciences integration adds a compelling growth driver, and if they can execute on the Nutrition turnaround and capitalize on the CGM market opportunity, there's a clear path to acceleration.
That's a wrap on Abbott's Q1 2026 earnings. Thanks for tuning in to Beta Finch, and we'll see you next time for more AI-powered earnings analysis!
Until next time, keep those portfolios diversified! --- *[Total word count: approximately 1,200 words]*